UT-Southwestern Medical Center: Repurposed Drug Has Promising Efficacy in Non-Small Cell Lung Cancer
December 10, 2024
December 10, 2024
DALLAS, Texas, Dec. 10 (TNSres) -- The University of Texas Southwestern Medical Center issued the following news release:
* * *
UTSW-led clinical trial suggests broader use for selinexor in cancers with KRAS mutations
* * *
An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Ce . . .
* * *
UTSW-led clinical trial suggests broader use for selinexor in cancers with KRAS mutations
* * *
An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Ce . . .